NurExone Biologic Inc. (TSXV: NRX | OTCQB: NRXBF | FSE: J90), a Toronto and Haifa-based biotechnology company developing exosome-based regenerative therapies, announced it will participate across four major Boston life sciences conferences from September 22–25, 2026. CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner are both confirmed speakers at multiple events. The company also disclosed a new investor relations agreement with RedChip Companies, Inc., valued at a one-time cash fee of US$65,000, subject to TSX Venture Exchange acceptance.

Key Points

  • NurExone Biologic Inc. (TSXV: NRX | OTCQB: NRXBF | FSE: J90) is a biotechnology company developing exosome-based regenerative therapies for central nervous system injuries
  • Dr. Shaltiel will speak at three Boston conferences and attend the invitation-only World Medical Innovation Forum; Dr. Kizhner will speak at the 8th Exosome-Based Therapeutics Development Summit
  • NurExone has engaged RedChip Companies, Inc. under a 90-day, US$65,000 cash agreement covering a national TV advertising campaign of approximately 40 airings on Fox Business or CNBC
  • Investors may watch for progress on the company's lead candidate, ExoPTEN™, which the company states is advancing toward clinical development for acute spinal cord injury

NurExone Executives to Speak Across Boston's Exosome and Biotech Conferences

Dr. Shaltiel is confirmed as a panellist at the 8th Exosome-Based Therapeutics Development Summit on September 24, where he will lead a roundtable on investor perspectives in the exosome therapeutics field. He will also participate in the LSX Congress USA panel "Proof to Payoff: Building and Financing Translation-Ready Biotechs" on September 23, and present on exosome bioprocess development at BioProcess International on September 25. Dr. Kizhner will speak at the Exosome-Based Therapeutics Development Summit as part of its expert faculty, contributing scientific and manufacturing perspectives to the programme.

Invitation-Only World Medical Innovation Forum Adds Profile to Boston Week

Dr. Shaltiel will also attend the World Medical Innovation Forum on September 22–23, a gathering presented by Mass General Brigham and Bank of America that convenes senior healthcare executives, clinicians, scientists, and investors to examine emerging technologies, regulatory challenges, and investment themes shaping healthcare. Attendance at this invitation-only forum, alongside three separate speaking engagements, positions NurExone's leadership for concentrated stakeholder engagement over a single week. Following the Boston events, Dr. Shaltiel will be available for one-on-one investor meetings in New York from September 28 through September 30.

RedChip Television Campaign Targets Retail and Institutional Investor Awareness

Separately, NurExone announced a non-exclusive investor relations agreement dated September 8, 2026, with RedChip Companies, Inc., a Florida-based investor relations and media firm founded in 1992. Under the agreement, RedChip will produce and distribute a 30-second television advertisement as part of a two-week national campaign expected to include approximately 40 airings on either Fox Business or CNBC. The company will pay a one-time cash fee of US$65,000; RedChip will receive no securities. The agreement carries an initial 90-day term and is subject to TSX Venture Exchange acceptance before services commence.